Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

As a university law lecturer, Nat is struggling to make ends meet. Her monthly salary of 33,000 baht is only a fraction of the cost of the super-expensive cancer drug she has been taking.In August ...

Purpose: The use of neoadjuvant anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has not been extensively explored. The current case report highlights the notable pathological ...

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non ...

10,12 In patients with T-cell/histiocyte-rich large B-cell lymphoma, B symptoms and hepatosplenomegaly are commonly observed. Patients with anaplastic lymphoma kinase (ALK)-positive large B-cell ...

Get Instant Summarized Text (Gist) A clinical trial demonstrated that combining chemotherapy with immunotherapy significantly improves treatment outcomes for diffuse large B-cell lymphoma (DLBCL ...

Race and ethnicity affect the distribution of molecular alterations seen in patients with non–small cell lung cancer (NSCLC). Although anaplastic lymphoma kinase (ALK) alterations are known to occur ...

Fenretinide is under clinical development by SciTech Development and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase I drugs for Anaplastic Large Cell ...

Background: Clinical trials frequently reported anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal postmarketing data. We ...